Wire · opportunities
You Can't Call It Cheatin': FDA Draft Guidance Provides a Framework for Leveraging Prior ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 July 2026 · Fusion42 review
FDA issued draft guidance on 2 June 2026 allowing developers of genome editing therapies to reuse prior knowledge—both public science and proprietary platform data—across chemistry, manufacturing, nonclinical, and clinical development to streamline regulatory approval and reduce duplicative testing.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're building a genome editing therapy for a rare disease, FDA just cut the time and cost of proving safety by letting you reuse nonclinical and manufacturing data from your previous program—as long as you can show the edits and cell source are the same. File your IND with that framework and you clear years of redundant testing.
◆ Coverage
1 source · 14 Jul 2026
◆ Related on Wire
◆ Topics